Printer Friendly

SCHERER ANNOUNCES LAUNCH OF ANOTHER PRODUCT UTILIZING ITS ZYDIS(R) TECHNOLOGY

 TROY, Mich., Aug. 10 /PRNewswire/ -- R.P. Scherer Corporation (NYSE: SHR) announced today that a new formulation of Pepcidine(R) (famotidine) utilizing Scherer's Zydis(R) fast dissolving dosage form technology has been launched in Sweden by Merck, Sharp & Dohme and will be rolled-out initially in other Scandinavian countries shortly afterwards. The new formulation, known generally as Pepcidine RPD(TM), and in Sweden as Pepcidin Rapitab(TM), is the first H2-antagonist to dissolve instantly in the mouth without the aid of water. Pepcidine(R) is a widely used product for the treatment of peptic ulcers and gastro- oesophageal reflux disease, and has been available in Sweden in conventional tablet form since 1987.
 Leading physicians say the new convenient formulation may help combat the problem of noncompliance, commonly seen with patients on long-term treatment, and with those who dislike taking tablets or capsules, or who have difficulty in swallowing. Compliance is a problem because patients with ulcers usually need to take the drug acutely for four to eight weeks, and may also take it for many months as maintenance therapy. As soon as their symptoms disappear, patients may discontinue their medication before the ulcer has fully healed.
 A spokesman for Scherer stated, "This is the second new Zydis(R) product to be launched within the last year. We have an extensive portfolio of products in development and expect many of the top international pharmaceutical companies to have at least one product marketed in this dosage form within the next five years."
 Merck is a worldwide, research-intensive health products company that discovers, develops, produces and markets human and animal health products and specialty chemicals.
 R.P. Scherer Corporation, an international developer and manufacturer of drug delivery systems, is the world's largest producer of soft gelatin capsules ("softgels"). The Company is currently developing and commercializing advanced drug delivery systems, including SCHERERSOL(TM), ZYDIS(R) and PULSINCAP(TM) technologies. The Company's proprietary drug delivery systems improve the efficacy of drugs by regulating the dosage, rate of absorption and place of release. The Company operates a global network of 18 facilities in 11 countries.
 Pepcidine RPD and Pepcidin Rapitab are trademarks and Pepcidine is a registered trademark of Merck & Co., Inc. (NYSE: MRK), Whitehouse Station, N.J., USA.
 Scherersol and Pulsincap are trademarks and Zydis is a registered trademark of R.P. Scherer Corporation.
 -0- 8/10/93
 /CONTACT: Nicole Williams, Executive VP & CFO, R.P. Scherer, 313-649-0900/
 (SHR)


CO: R.P. Scherer Corporation; Merck, Sharp & Dohme ST: Michigan IN: MTC SU: PDT

ML -- DE006 -- 1067 08/10/93 09:19 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 10, 1993
Words:426
Previous Article:FIRST UNION ANNOUNCES GRAND OPENING OF NEW ANCHOR TENANT AT MOUNTAINEER MALL
Next Article:THE SILVERLAKES DEVELOPMENT AND G.L. HOMES ANNOUNCE MEGA-DEAL; G.L. HOMES TO BUY UP TO 2,790 LOTS FOR RESIDENTIAL CONSTRUCTION
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters